| __timestamp | Axsome Therapeutics, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 44820000 |
| Thursday, January 1, 2015 | 2419289 | 82080000 |
| Friday, January 1, 2016 | 6343648 | 97130000 |
| Sunday, January 1, 2017 | 7206691 | 121271000 |
| Monday, January 1, 2018 | 9351522 | 153548000 |
| Tuesday, January 1, 2019 | 13598030 | 202541000 |
| Wednesday, January 1, 2020 | 28896749 | 245164000 |
| Friday, January 1, 2021 | 66646205 | 285773000 |
| Saturday, January 1, 2022 | 159253661 | 325998000 |
| Sunday, January 1, 2023 | 323123000 | 332540000 |
| Monday, January 1, 2024 | 411359000 |
In pursuit of knowledge
In the competitive landscape of biopharmaceuticals, understanding the financial strategies of companies like Axsome Therapeutics, Inc. and PTC Therapeutics, Inc. is crucial. Over the past decade, both companies have shown a significant increase in their Selling, General, and Administrative (SG&A) expenses, reflecting their growth and strategic investments.
From 2014 to 2023, Axsome Therapeutics saw a staggering increase in SG&A expenses, growing by over 23,000%, from just over $1 million to approximately $323 million. This rapid escalation highlights their aggressive expansion and investment in market penetration. Meanwhile, PTC Therapeutics, with a more stable growth trajectory, increased their SG&A expenses by about 640%, reaching around $333 million in 2023.
This financial evolution underscores the dynamic nature of the biopharmaceutical industry, where strategic spending is pivotal for innovation and market leadership.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Zoetis Inc. and PTC Therapeutics, Inc.
Breaking Down SG&A Expenses: Viatris Inc. vs PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Breaking Down SG&A Expenses: PTC Therapeutics, Inc. vs MiMedx Group, Inc.